Leita í fréttum mbl.is

Getur Trump annað en sigrað?

ef þetta gengur eftir:

"CAMBRIDGE, Mass. & SOMERSET, N.J.--(BUSINESS WIRE)--Jun. 25, 2020-- Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, and Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate (mRNA-1273) at Catalent’s biologics facility in Bloomington, Indiana.

As part of the agreement, Catalent will provide vial filling and packaging capacity, as well as additional staffing required for 24x7 manufacturing operations at the site to support production of an initial 100 million doses of the vaccine candidate intended to supply the U.S. market starting in the third quarter of 2020. The companies are in discussions to secure fill-finish capacity for continued production of hundreds of millions of additional doses.

Catalent will also provide clinical supply services from its facilities in Philadelphia, Pennsylvania, including packaging and labeling, as well as storage and distribution to support Moderna’s Phase 3 clinical study for this candidate.

“We appreciate this collaboration with Catalent and the flexibility of their team to deliver critical fill-finish capacity for mRNA-1273 at unprecedented speed,” said Juan Andres, Moderna’s Chief Technical Operations and Quality Officer. “It has been wonderful to see both teams working together to support the common good.”

Catalent is proud to partner with Moderna in its work to address this critical public health need,” commented John Chiminski, Chair and Chief Executive Officer of Catalent. “Catalent’s proven expertise in manufacturing scale-up and commercial production are well suited to support Moderna’s efforts to prepare for wide-scale supply of this vaccine candidate so that it is available if appropriate to address the pandemic.”

Catalent’s state-of-the-art 875,000 square-foot biologics facility in Bloomington will undertake this vial filling work under barrier isolator technology. Moderna will leverage the site’s recent packaging expansion, which provides fully automated and high-speed packaging capabilities to accelerate manufacturing timelines. The facility has deep expertise in sterile formulation, with drug substance development and manufacturing and drug product fill-finish capacity across liquid and lyophilized vials, prefilled syringes, and cartridges, as well as primary and secondary packaging. In addition to its Bloomington location, the Catalent Biologics network has facilities in Brussels, Belgium and Anagni, Italy that perform sterile drug product manufacturing and packaging, and in the United States and Europe for manufacturing proteins, viral vectors for gene therapies and cell therapies, as well as providing pre-filled syringe manufacture and biologics analytical services.

About mRNA-1273, Moderna’s Vaccine Candidate Against COVID-19

mRNA-1273 is an mRNA vaccine candidate against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was selected by Moderna in collaboration with investigators from Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH).

On June 11, 2020, Moderna announced that enrollment of younger adults (n=300) and the sentinel group of older adults (n=50) in its Phase 2 study of mRNA-1273 was complete, and that its Phase 3 study of approximately 30,000 participants, is expected to begin in July 2020."

 

Ef þetta gengur eftir og COVID19 verður bægt frá Bandaríkjunum 

hverjum verður þakkað í kosningunum?

Joe og Hunter BIDEN?

Getur Trump annað en sigrað ef þetta bóluefni lukkast?


« Síðasta færsla | Næsta færsla »

Athugasemdir

1 Smámynd: Halldór Jónsson

MAGA, MAGA

Halldór Jónsson, 26.6.2020 kl. 14:09

2 identicon

Hvers vegna ætti einhver að tengja góðan árangur vísindamanna í þróun bóluefnis við Trump? Sérstaklega þegar kosningarnar eru löngu áður en almenningur sér eitthvað bóluefni og almennar bólusetningar gætu hafist.

Sennilega verða vel yfir 200.000 Bandaríkjamenn látnir vegna trassaskapar og glæpsamlegs aðgerðarleysis forsetans þegar kosið verður. Það mun væntanlega hafa meiri áhrif en þróunarstarf einkafyrirtækis með engin tengsl við Trump.

Vagn (IP-tala skráð) 26.6.2020 kl. 21:59

3 Smámynd: Halldór Jónsson

Ekki ristirðu djúpt í pólitík Vagn ef þú heldur þessu fram

Halldór Jónsson, 26.6.2020 kl. 22:48

4 Smámynd: Helga Kristjánsdóttir

Nei,auðvitað gerði who ekkert en það á eftir að birtast betur. 

Hatrið á Trump myndi magnast læknuðust allir fyrir tilstilli lyfuppfinninga borgara BNA. 

Helga Kristjánsdóttir, 27.6.2020 kl. 00:46

5 identicon

MODERNA sýndi árangur og TRUMP sýndi styrk með fjárveitingu. ÍSRAELS Gyðingar og AMERIKA eru ávallt í fremstu röð, þegar kemur að vísindum.

TRUMP vinnur ofursigur í næstu kosningum vegna ákvarðanna og mikillar vinnu fyrir AMERIKUMENN. "Made in USA" er framtíðin. Vísindi og uppfinningar sitja NÚ í AMERIKU. Penesilin var allt framleitt í Kína - EKKI LENGUR. TRUMP fer á eigin vegum til STÓR sigurs í AMERIKU í nóvember. 

PLÁGAN frá Kína verður sigruð á ÞESSU ÁRI af KÁRA og ERFÐARGREININGU - MODERNA og AMERIKU. Snúum til VESTURS með hugsun TRUMPS og hægri bjartsýni fyrir heiminn.

GÍSLI HOLGERSSON - ICELAND (IP-tala skráð) 27.6.2020 kl. 10:48

Bæta við athugasemd

Ekki er lengur hægt að skrifa athugasemdir við færsluna, þar sem tímamörk á athugasemdir eru liðin.

Höfundur

Halldór Jónsson
Halldór Jónsson

verkfræðingur, flugdellukall, tennis-og badmintonspilari

-ekki góður í neinu af þessu-

Heimsóknir

Flettingar

  • Í dag (16.5.): 623
  • Sl. sólarhring: 658
  • Sl. viku: 5531
  • Frá upphafi: 3195150

Annað

  • Innlit í dag: 482
  • Innlit sl. viku: 4533
  • Gestir í dag: 436
  • IP-tölur í dag: 425

Uppfært á 3 mín. fresti.
Skýringar

Eldri færslur

Innskráning

Ath. Vinsamlegast kveikið á Javascript til að hefja innskráningu.

Hafðu samband